Senhwa Biosciences, Inc. (TPEX:6492)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
49.95
-0.35 (-0.70%)
Apr 28, 2026, 1:30 PM CST
54.88%
Market Cap 4.46B
Revenue (ttm) 1.07M
Net Income (ttm) -264.77M
Shares Out 89.39M
EPS (ttm) -2.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 264,659
Average Volume 447,622
Open 51.00
Previous Close 50.30
Day's Range 49.85 - 51.30
52-Week Range 31.35 - 66.50
Beta 1.09
RSI 42.41
Earnings Date May 12, 2026

About Senhwa Biosciences

Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and targeted agents. The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; CX-5461, which is in a phase I study for solid tumors; CX-5461 that is in a phase Ib expansion study of CX-5461 in patients with solid tumors and BRCA2 and /or PALB2 mutation; and CX-5461, which is in Phase I trial of pidna... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6492
Full Company Profile

Financial Performance

In 2025, Senhwa Biosciences's revenue was 1.07 million, an increase of 7.00% compared to the previous year's 1.00 million. Losses were -264.77 million, -9.86% less than in 2024.

Financial Statements

News

Basal Cell Neoplasms Clinical Trial Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

New York, USA, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Basal Cell Neoplasms Clinical Trial Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight Basal Cell N...

8 months ago - Benzinga